Skip to main content

Table 5 Survival of patients with IIM at previous reports and this study

From: Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China

First author, published year (Ref) location Follow-up Mean follow-up No. of patients Clinical-pathologic subgroup Survival rates (%)
       1-year 5-year > 5-year
Medsger 1971 [10] USA 1947-1968 7 years 124 PM, DM, JDM, OM, CAM 72 65 53(7 yr)
Benbassat1985 [8] Israel 1956-1976 20 years 92 PM, DM, JDM, OM, CAM 72 52 --
Hochberg1986 [11] USA 1970-1981 8 years 76 PM, DM, JDM, OM 94.5 80.4 72.8 (8 yr)
Maugars 1996 [9] France 1973-1998 -- 69 PM, DM, JDM, OM, CAM 82.6 66.7 55.4 (9 yr)
Uthman 1996[31] France 1980-1992 5.2 years 30 PM, DM, CAM, OM -- 89 85(10 yr)
Marie 2001 [12] France 1983-1999 4 years 77 PM, DM, CAM 83 77 61 (15 y)
Sultan 2002 [1] England 1978-1999 20 years 46 PM, DM, JDM, OM   95 83.8 (10 yr)
Dankó2004 [15] Hungary 1976-2002 8.46 years 162 PM, DM, JDM, OM, CAM 95 92 89 (10 yr)
Troyanov2005[7] France 1967-2001 8.7 years 100 PM. DM, CAM, OM -- -- 73(10 yr)
Airio. 2006 [32] Finland 1965-1995 11 years 248
(176PM/72DM)
PM, DM -- 75(PM)
63(DM)
55(PM
53(DM)
Torres, et al 2006 [33] Spain 1976-2005 9 years 107 PM, DM, JM, OM, OM, CAM 92 80 71(10 years)
Yamasaki Y, et al 2011[29] Japan 1984-2010 --- 197 PM, DM, ADM, CADM, OM 85 75 67(10 years)
Ours 2011 China 1986-2010 7.5 years 188 PM, DM, ADM, JM, OM, CAM 93.6% 88.7 81(10 years), 76.6(15 years)
65.6 (20 years)
  1. Ref, reference; PM, polymyositis; DM, dermatomyositis; CAM, cancer associated myositis; OM, overlap myositis; JM, Juvenile PM/DM.